N-（1-苄基-2,3-二氢-1H-吡咯并[2,3-b]喹啉-4-基）-2-苯基乙酰胺 | 365565-02-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-（1-苄基-2,3-二氢-1H-吡咯并[2,3-b]喹啉-4-基）-2-苯基乙酰胺
• 英文名称: PGP-4008
• 英文别名: N-(1-Benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-4-yl)-2-phenyl-acetamide；N-(1-Benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-4-yl)-2-phenylacetamide；N-(1-benzyl-2,3-dihydropyrrolo[2,3-b]quinolin-4-yl)-2-phenylacetamide
• CAS: 365565-02-2
• 化学式: C₂₆H₂₃N₃O
• 分子量: 393.488
• InChiKey: HVIAKQBMYMKWII-UHFFFAOYSA-N

物化性质

• 溶解度：
  二甲基亚砜：50mM；乙醇：5mM

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  45.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-(1-benzyl-pyrrolidin-2-ylideneamino)benzonitrile 在 sodium hydride 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 环己烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.08h， 生成 N-（1-苄基-2,3-二氢-1H-吡咯并[2,3-b]喹啉-4-基）-2-苯基乙酰胺
  参考文献：
  名称：

  Synthesis and Evaluation of Dihydropyrroloquinolines That Selectively Antagonize P-Glycoprotein

  摘要：

  In a search for improved multiple drug resistance (MDR) modulators, we identified a novel series of substituted pyrroloquinolines that selectively inhibits the function of P-glycoprotein (Pgp) without modulating multidrug resistance-related protein 1 (MRP1). These compounds were evaluated for their toxicity toward drug-sensitive tumor cells (i.e. MCF-7, T24) and for their ability to antagonize Pgp-mediated drug-resistant cells (i.e. NCI/ADR) and MRP1-mediated resistant cells (i.e. MCF-7NP). Cytotoxicity and drug accumulation assays demonstrated that the dihydropyrroloquinolines inhibit Pgp to varying degrees, without any significant inhibition of MRP1. The compound termed PGP-4008 was the most effective at inhibiting Pgp in vitro and was further evaluated in vivo. PGP-4008 inhibited tumor growth in a murine syngeneic Pgp-mediated MDR solid tumor model when given in combination with doxorubicin. PGP4008 was rapidly absorbed after intraperitoneal administration, with its plasma concentrations exceeding the in vitro effective dose for more than 2 h. PGP-4008 did not alter the plasma distribution of concomitantly administered anticancer drugs and did not cause systemic toxicity as was observed for cyclosporin A. Because of their enhanced selectivity toward Pgp, these substituted dihydropyrroloquinolines may be effective MDR modulators in a clinical setting.

  DOI：

  10.1021/jm0303204

文献信息

• Novel compounds for enhancing chemotherapy
  申请人：——

  公开号：US20020013322A1

  公开（公告）日：2002-01-31

  The present invention provides chemical compounds, pharmaceutical compositions, and methods for increasing the therapeutic efficacy of drugs. Specifically, the invention provides compounds and compositions for inhibiting drug transport proteins that efflux therapeutic agents from cells, and to methods for using these compounds and pharmaceutical compositions to increase the efficacy of the therapeutic agents that are effluxed by these drug transport proteins.

  本发明提供了化学化合物、药物组合物和方法，用于增强药物的治疗效果。具体地，本发明提供了抑制药物转运蛋白的化合物和组合物，这些蛋白从细胞中排出治疗剂量的药物，并提供使用这些化合物和药物组合物的方法，以增加被这些药物转运蛋白排出的治疗剂量的药物的疗效。
• Compounds for enhancing chemotherapy
  申请人：The Penn State Research Foundation.

  公开号：US20030105122A1

  公开（公告）日：2003-06-05

  The present invention provides 2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-4-ylamines, of the formula: 1 or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , and R 7 are as defined herein. Also disclosed are pharmaceutical compositions comprising such compounds, and methods for using the compounds to increase the therapeutic efficacy of drugs.

  本发明提供了2,3-二氢-1H-吡咯并[2,3-b]喹啉-4-胺，化学式为：1或其药学上可接受的盐，其中R1、R2、R3和R7如本文所定义。还披露了包含这些化合物的药物组合物，以及使用这些化合物来增强药物的治疗效果的方法。
• 3,4-DIHYDROISOQUINOLINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1306373A1

  公开（公告）日：2003-05-02

  A 3,4-dihydroisoquinoline derivative compound of formula (I) or a non-toxic salt thereof and a pharmaceutical agent comprising it as active ingredient (wherein all symbols have the same meaning as described in the specification). The compound of formula (I) has agonizing activity on CB2 receptor and therefore it is useful for the prophilaxis and/or treatment of various diseases such as asthma, nasal allergy, atopic dermatitis, autoimmune diseases, rheumatoid arthritis, immune dysfunction, postoperative pain, carcinomatous pain, etc.

  一种式（I）的 3,4-二氢异喹啉衍生物化合物或其无毒盐，以及以其为活性成分的药物制剂（其中所有符号的含义与说明书所述相同）。式（I）化合物对 CB2 受体具有激动活性，因此可用于预防和/或治疗各种疾病，如哮喘、鼻过敏、特应性皮炎、自身免疫性疾病、类风湿性关节炎、免疫功能障碍、术后疼痛、癌性疼痛等。
• Compositions and methods for treating conditions related to adrenocortical activity and/or excessive steroid production
  申请人：The Regents of the University of Michigan

  公开号：US10512667B2

  公开（公告）日：2019-12-24

  Provided herein are methods for treating subjects having conditions related to adrenocortical activity and/or excessive steroid production. In particular, provided herein are methods for treating subjects having conditions related to adrenocortical activity and/or excessive steroid production through administration of at least one of the following agents: 1) an agent capable of inhibiting cholesterol efflux related to ABCA1 and/or ABCG1; 2) an agent capable of inhibiting MDR1 related cortisol secretion and/or MDR1 P-glycoprotein multiple drug transporter activity; and 3) an agent capable of inhibiting mitochondrial activity.

  本文提供了治疗与肾上腺皮质活性和/或类固醇分泌过多有关的疾病的方法。特别是，本文提供了通过施用以下至少一种制剂治疗肾上腺皮质活性和/或类固醇分泌过多相关疾病的方法：1）能够抑制与 ABCA1 和/或 ABCG1 相关的胆固醇外流的制剂；2）能够抑制与 MDR1 相关的皮质醇分泌和/或 MDR1 P 糖蛋白多药物转运体活性的制剂；以及 3）能够抑制线粒体活性的制剂。
• NOVEL COMPOUNDS FOR ENHANCING CHEMOTHERAPY
  申请人：THE PENN STATE RESEARCH FOUNDATION

  公开号：EP1272479A2

  公开（公告）日：2003-01-08